Marcel Wijma
Marcel Wijma is founder and managing director of Van Leeuwenhoeck Inc. (VLI). VLI is actively engaged in the financial research of life sciences companies in Europe, North America and Australia. VLI provides institutional investors and other professional investors with independent, unbiased research on the real value of innovative life sciences companies. In 2009, Wijma was named one of the top three biotech analysts in Europe by the Financial Times/Starmine. He leads the professional VLR research team, which is augmented by selected external financial researchers with a specialization in life sciences. Wijma has a master's degree in financial economics from Erasmus University in Rotterdam.
Recent Quotes
"RXII Pharmaceuticals Corp. announced that it has extended its existing agreement with the Norwegian biotech company PCI Biotech."
—
Marcel Wijma, Van Leeuwenhoeck Research
(5/22/17)
more >
"RXII developed a robust RNAi therapeutic platform including self-delivering RNA (sd-rxRNA) compounds."
—
Marcel Wijma, Van Leeuwenhoeck Research
(5/17/17)
more >
"RVX remains gravely undervalued at the current share price."
—
Marcel Wijma, Van Leeuwenhoeck Research
(5/1/17)
more >
"RXII is substantially undervalued; its total value should be $75-100M."
—
Marcel Wijma, Van Leeuwenhoeck Research
(2/13/17)
more >
"With a successful Phase III trial and considering the market potential for RVX-208, a very significant upside potential for RVX-208 and RVX is attainable."
—
Marcel Wijma, Van Leeuwenhoeck Research
(5/11/16)
more >
"RVX's strategy is to start with the clinical trial, derive data, and create value to increase the likelihood of a partnership deal with a large pharmaceutical company."
—
The Life Sciences Report Interview with Marcel Wijma
(2/17/16)
more >
"RGS could be Australia's second success story in the stem cell industry."
—
The Life Sciences Report Interview with Marcel Wijma
(2/17/16)
more >
"Results of MSB's Phase 2 diabetes trial have been published online."
—
Marcel Wijma, The Daily Molecule (Van Leeuwenhoeck Research)
(7/24/15)
more >
